Search

Your search keyword '"Thompson, Melanie A"' showing total 591 results
Start Over Author "Thompson, Melanie A"
591 results on '"Thompson, Melanie A"'

1. Primary Care Guidance for Providers of Care for Persons With Human Immunodeficiency Virus: 2024 Update by the HIV Medicine Association of the Infectious Diseases Society of America

Author

Horberg, Michael, Thompson, Melanie, Agwu, Allison, Colasanti, Jonathan, Haddad, Marwan, Jain, Mamta, McComsey, Grace, Radix, Asa, Rakhmanina, Natella, Short, William R, Singh, Tulika, and Tookes, Hansel

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Clinical Sciences, Prevention, Pediatric, Aging, Health Services, Sexually Transmitted Infections, Clinical Research, HIV/AIDS, Women's Health, Infectious Diseases, 7.3 Management and decision making, Infection, Good Health and Well Being, HIV care engagement, HIV comorbidities, HIV monitoring, HIV primary care, preventive health, sexually transmitted infections, Biological Sciences, Medical and Health Sciences, Microbiology, Clinical sciences
Abstract

Advances in antiretroviral therapy (ART) have made it possible for persons with human immunodeficiency virus (HIV) to live a lifespan approaching that of people without HIV, without progressing to AIDS or transmitting HIV to sexual partners or infants. There is, therefore, increasing emphasis on maintaining health throughout the lifespan. To receive optimal medical care and achieve desired outcomes, persons with HIV must be consistently engaged in care and able to access uninterrupted treatment, including ART. Comprehensive evidence-based HIV primary care guidance is, therefore, more important than ever. Creating a patient-centered, stigma-free care environment is essential for care engagement. Barriers to care must be decreased at the societal, health system, clinic, and individual levels. As the population ages and noncommunicable diseases arise, providing comprehensive health care for persons with HIV becomes increasingly complex, including management of multiple comorbidities and the associated challenges of polypharmacy, while also attending to HIV-specific health concerns. Clinicians must address issues specific to preventive health, including cancer screening, providing recommended vaccinations, as well as promoting sexual health, including sexually transmitted infection diagnosis, treatment, and prevention. Clinicians also must address issues for specific populations, including persons of childbearing potential, including during preconception and pregnancy; children; adolescents; and transgender and gender-diverse individuals. This guidance from an expert panel of the HIV Medicine Association of the Infectious Diseases Society of America updates the previous 2020 HIV Primary Care Guidance.

Published
2024

2. Ending the HIV Epidemic in Metropolitan Atlanta: a mixed‐methods study to support the local HIV/AIDS response

Author

Piske, Micah, Nosyk, Bohdan, Smith, Justin C., Yeung, Bianca, Enns, Benjamin, Zang, Xiao, Sullivan, Patrick S., Armstrong, Wendy S., Thompson, Melanie A., Daniel, Gaea, and Del Rio, Carlos

Subjects
United States. Centers for Disease Control and Prevention, Prevention, Methods, HIV tests -- Methods, Market surveys -- Methods, Public health -- Methods, HIV -- Prevention, Epidemiology -- Methods, HIV (Viruses) -- Prevention, HIV testing -- Methods
Abstract

INTRODUCTION The Atlanta, Georgia, Metropolitan Statistical Area (MSA) is the eighth largest in the United States and one of the country's fastest‐growing metropolitan areas [1, 2]. The Ryan White HIV/AIDS [...], : Introduction: Four counties within the Atlanta, Georgia 20‐county eligible metropolitan area (EMA) are currently prioritized by the US “Ending the HIV Epidemic” (EHE) initiative which aims for a 90% reduction in HIV incidence by 2030. Disparities driving Atlanta's HIV epidemic warrant an examination of local service availability, unmet needs and organizational capacity to reach EHE targets. We conducted a mixed‐methods evaluation of the Atlanta EMA to examine geographic HIV epidemiology and distribution of services, service needs and organization infrastructure for each pillar of the EHE initiative. Methods: We collected 2021 county‐level data (during June 2022), from multiple sources including: AIDSVu (HIV prevalence and new diagnoses), the Centers for Disease Control and Prevention web‐based tools (HIV testing and pre‐exposure prophylaxis [PrEP] locations) and the Georgia Department of Public Health (HIV testing, PrEP screenings, viral suppression and partner service interviews). We additionally distributed an online survey to key local stakeholders working at major HIV care agencies across the EMA to assess the availability of services, unmet needs and organization infrastructure (June−December 2022). The Organizational Readiness for Implementing Change questionnaire assessed the organization climate for services in need of scale‐up or implementation. Results: We found racial/ethnic and geographic disparities in HIV disease burden and service availability across the EMA—particularly for HIV testing and PrEP in the EMA's southern counties. Five counties not currently prioritized by EHE (Clayton, Douglas, Henry, Newton and Rockdale) accounted for 16% of the EMA's new diagnoses, but Conclusions: Service delivery across all EHE pillars must substantially expand to reach national goals and address HIV disparities in metro Atlanta. High‐resolution geographic data on HIV epidemiology and service delivery with community input can provide targeted guidance to support local EHE efforts.

Published
2024
Full Text
View/download PDF

3. Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials

Author

Martins, Marcelo D, Cahn, Pedro E, Lopardo, Gustavo D, Porteiro, Norma, Bloch, Mark Theo, Baker, David Alfred, Roth, Norman, Moore, Richard J, Finlayson, Robert James, McMahon, James, Rieger, Armin, Zoufaly, Alexander, Schmied, Brigitte, Hartl, Sylvia, Zangerle, Robert, Smaill, Fiona, Walmsley, Sharon L, Conway, Brian, Rachlis, Anita, Smith, Graham H R, Perez Cortes, Carlos, Afani, Alejandro, Campos Barker, Maria Isabel E, Chahin Anania, Carolina Eugenia, Reyes, Marcelo J. Wolff, Gerstoft, Jan, Weis, Nina, Laursen, Alex Lund, Molina, Jean-Michel, Yazdanpanah, Yazdan, Cotte, Laurent, Raffi, Francois, Slama, Laurence, Morlat, Philippe, Girard, Pierre-Marie, Katlama, Christine, Rockstroh, Juergen K, Arasteh, Keikawus, Esser, Stefan, Stoehr, Albrecht, Stellbrink, Hans-Juergen, Stoll, Matthias, Schuermann, Dirk, Faetkenheuer, Gerd, Bogner, Johannes Richard, Lutz, Thomas, Baumgarten, Axel, Jaeger, Hans, Wiese, Carmen, Gori, Andrea, Migliorino, Guglielmo Marco, Coltan, Gabriel, Constandis, Felicia, Erscoiu, Simona M, Prisacariu, Liviu-Jany, Rugina, Sorin, Streinu-Cercel, Adrian, Pokrovsky, Vadim V, Zakharova, Natalia, Shuldyakov, Andrey Anatolyevich, Ryamova, Elena Pavlovna, Kulagin, Valeriy Viktorovich, Tsybakova, Olga Aleksandrovna, Orlova-Morozova, Elena, Nagimova, Firaya, Voronin, Evgeniy, Shimonova, Tatiana Evgenyevna, Kozyrev, Oleg Anatolyevich, Orrell, Catherine, Lombaard, Johannes Jurgens, Botes, Margaretha Elizabeth, de Jager, Marleen, Segorb, Joaquin Portilla, Gatell Artigas, Josep Maria, Mallolas Masferrer, Josep, Guillen, Santiago Moreno, Perez Elias, Maria Jesus, Arribas Lopez, Jose R, Puigmal, Eugenia Negredo, Podzamczer Palter, Daniel, Ortega, Frederico Pulido, Garcia, Jesus Troya, de los Santos Gil, Ignacio, Berenguer, Juan, Nelson, Mark Richard, Williams, Ian G, Johnson, Margaret A, Khoo, Saye, Schembri, Gabriel, Clarke, Amanda, Gompels, Mark, Fox, Julie Meriel, Lwanga, Julianne, Taylor, Steven John, Dockrell, David Harold, Kegg, Stephen, Hagins, Debbie P, Osiyemi, Olayemi O, Prelutsky, David James, Ramgopal, Moti N, Scarsella, Anthony J, Dretler, Robin, DeJesus, Edwin, Bettacchi, Christopher J, Sims III, James, Clay, Patrick G, Bellos, Nicholaos C, Thompson, Melanie A, Montero, Jose, McDonald, Cheryl K, Creticos, Catherine, Shamblaw, David, Terrelonge, Antonio E, Valdes, Martin, Tashima, Karen T, Robbins, William J, Elion, Richard A, Goldstein, Deborah, Slim, Jihad, Lalezari, Jacob Paul, Pushkin, Richard, Lalla-Reddy, Sujata N, Win, Sanda S, Ruane, Peter Jerome, Mills, Anthony Martin, Cade, Jerry L, Campo, Rafael, Dietz, Craig A, Hoffman-Terry, Margaret, Blick, Gary, Rubin, David Scott, Mayer, Cynthia, Rondon, Juan Carlos, Cook, Paul P, Daar, Eric, Kumar, Princy N, Swindells, Susan, Castro, Jose Guillermo, Morales-Ramirez, Javier O, Santiago, Lizette, Santana-Bagur, Jorge L, Vandekerckhove, Linos, Florence, Eric, De Wit, Stephane, Derdelinckx, Inge, Vandercam, Bernard, Belkhir, Leila, De Wet, Joseph, Lebouche, Bertrand, Trottier, Benoit, Longpre, Daniele, Szabo, Jason, LeBlanc, Roger P, Jensen, Werner, Gonzalez, Alvaro Rojas, Beltran, Carlos, Sussmann, Otto Alberto, Velez, Juan Diego, Onate, Jose Millan, Nielsen, Henrik, Degen, Olaf, Stephan, Christoph, Arathoon, Eduardo, Lopez, Rudy Manuel, Rojas Alvarado, Evelyn Michelle, Gonzalez Patzan, Luis Demetrio, Meija, Carlos R, Pinzon, Rodolfo, Parchment, Charles, Sthoeger, Zev, Chowers, Michal, Riesenberg, Klaris, Shahar, Eduardo, Levy, Itzchak, Quintero Perez, Nora Patricia, Andrade-Villanueva, Jaime Federico, Crabtree Ramirez, Brenda Eloisa, Rijnders, Bart, den Hollander, Jan G, Handy, Rupert, Morales, Nilo Bonifacio, Hidalgo, Jose Alfredo, Infante, Rosa Mercedes, Matos Prado, Eduardo Demetrio, Campos, Pablo E, Ticona Chaves, Eduardo Romulo, Pinedo, Yvett, Pacheco, Patricia, Maltez, Fernando Manuel, Cunha, Jose, Neves, Isabel, Serrao, Rosario, Melendez-Rivera, Ivan, Mendoza-Rodriguez, Rafael O, Maldonado-Rivera, Sandra, Ortiz-Lasanta, Grisell, Kizhlo, Svetlana, Freud, Hernando Knobel, Moreno, Jose Sanz, Mendez, Francisco Vera, Mohapi, Lerato, Mitha, Essack Aziz, Mahomed, Akbar Anvar, Fouche, Leon Frederik, Kaplan, Richard, Siddique, Naeem, Hoosen, Farzana, Rassool, Mohammed Siddique, Baraldi, Ezio, Calmy, Alexandra, Cavassini, Matthias, Fehr, Jan, Tsai, Hung-Chin, Lin, Hsi-Hsun, Huang, Chun-Kai, Ko, Wen-Chien, Lin, Yu-Hui, Chen, Su-Jung, Hung, Chien-Ching, Avihingsanon, Anchalee, Kiertiburanakul, Sasisopin, Ratanasuwan, Winai, Supparatpinyo, Khuanchai, Chetchotisakd, Ploenchan, Changpradub, Dhitiwat, Orkin, Chloe, Fox, Ashini, Winston, Alan, Ustianowski, Andrew, Yangco, Bienvenido G, Asmuth, David Michael, Vigil, Karen J, Berger, Daniel S, Bhatti, Laveeza, Campbell, Thomas, Casey, Kathleen K, Liu, Edward, Crofoot, Gordon E, Cunningham, Douglas, Feinberg, Judith, Fichtenbaum, Carl, Balamban Felizarta, Franco Antonio, Jefferson, Thomas T, Johnson, Marc Alexander, Lewis, Stanley T, Luque, Amneris E, Novak, Richard M, Sloan, Louis, Sweet, Donna E, Towner, William J, Zane, Ryan, Riedel, David J, Loftus, Richard Anton, Shon, Alyssa So Young, Mogyoros, Miguel, Tebas, Pablo, Scott, Mia Louise, Parenti, David M, Inciarte Portillo, Alexy, Cahn, Pedro, Lombaard, Johannes, Kumar, Sushma, Campbell, Havilland, Wan, Hong, Teal, Valerie, Jin Xu, Zhi, Asante-Appiah, Ernest, Sklar, Peter, Teppler, Hedy, and Lahoulou, Rima

Published
2024
Full Text
View/download PDF

4. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

Author

Saag, Michael S, Gandhi, Rajesh T, Hoy, Jennifer F, Landovitz, Raphael J, Thompson, Melanie A, Sax, Paul E, Smith, Davey M, Benson, Constance A, Buchbinder, Susan P, del Rio, Carlos, Eron, Joseph J, Fätkenheuer, Gerd, Günthard, Huldrych F, Molina, Jean-Michel, Jacobsen, Donna M, and Volberding, Paul A

Subjects
Biomedical and Clinical Sciences, Public Health, Health Sciences, Clinical Sciences, Medical Microbiology, Prevention, Patient Safety, Infectious Diseases, Clinical Trials and Supportive Activities, HIV/AIDS, Sexually Transmitted Infections, Clinical Research, 6.1 Pharmaceuticals, Infection, Good Health and Well Being, AIDS-Related Opportunistic Infections, Age Factors, Anti-Retroviral Agents, Betacoronavirus, COVID-19, Comorbidity, Coronavirus Infections, Drug Administration Schedule, Drug Costs, Drug Resistance, Viral, Drug Substitution, Drug Therapy, Combination, Female, HIV Infections, Humans, International Agencies, Male, Pandemics, Pneumonia, Viral, Polypharmacy, Pre-Exposure Prophylaxis, Pregnancy, Pregnancy Complications, Infectious, RNA, Viral, SARS-CoV-2, Societies, Medical, United States, Viral Load, Medical and Health Sciences, General & Internal Medicine, Biomedical and clinical sciences, Health sciences
Abstract

ImportanceData on the use of antiretroviral drugs, including new drugs and formulations, for the treatment and prevention of HIV infection continue to guide optimal practices.ObjectiveTo evaluate new data and incorporate them into current recommendations for initiating HIV therapy, monitoring individuals starting on therapy, changing regimens, preventing HIV infection for those at risk, and special considerations for older people with HIV.Evidence reviewNew evidence was collected since the previous International Antiviral (formerly AIDS) Society-USA recommendations in 2018, including data published or presented at peer-reviewed scientific conferences through August 22, 2020. A volunteer panel of 15 experts in HIV research and patient care considered these data and updated previous recommendations.FindingsFrom 5316 citations about antiretroviral drugs identified, 549 were included to form the evidence basis for these recommendations. Antiretroviral therapy is recommended as soon as possible for all individuals with HIV who have detectable viremia. Most patients can start with a 3-drug regimen or now a 2-drug regimen, which includes an integrase strand transfer inhibitor. Effective options are available for patients who may be pregnant, those who have specific clinical conditions, such as kidney, liver, or cardiovascular disease, those who have opportunistic diseases, or those who have health care access issues. Recommended for the first time, a long-acting antiretroviral regimen injected once every 4 weeks for treatment or every 8 weeks pending approval by regulatory bodies and availability. For individuals at risk for HIV, preexposure prophylaxis with an oral regimen is recommended or, pending approval by regulatory bodies and availability, with a long-acting injection given every 8 weeks. Monitoring before and during therapy for effectiveness and safety is recommended. Switching therapy for virological failure is relatively rare at this time, and the recommendations for switching therapies for convenience and for other reasons are included. With the survival benefits provided by therapy, recommendations are made for older individuals with HIV. The current coronavirus disease 2019 pandemic poses particular challenges for HIV research, care, and efforts to end the HIV epidemic.Conclusion and relevanceAdvances in HIV prevention and management with antiretroviral drugs continue to improve clinical care and outcomes among individuals at risk for and with HIV.

Published
2020

5. Human monkeypox virus infection in women and non-binary individuals during the 2022 outbreaks: a global case series

Author

Thornhill, John P, Palich, Romain, Ghosn, Jade, Walmsley, Sharon, Moschese, Davide, Cortes, Claudia P, Galliez, Rafael Mello, Garlin, Amy B, Nozza, Silvia, Mitja, Oriol, Radix, Asa E, Blanco, Jose Luis, Crabtree-Ramirez, Brenda, Thompson, Melanie, Wiese, Lothar, Schulbin, Hubert, Levcovich, Ariela, Falcone, Marco, Lucchini, Anna, Sendagorta, Elena, Treutiger, Carl-Johan, Byrne, Ruth, Coyne, Katherine, Meyerowitz, Eric A, Grahn, Anna M, Hansen, Ann-Brit Eg, Pourcher, Valerie, DellaPiazza, Michelle, Lee, Rachel, Stoeckle, Marcel, Hazra, Aniruddha, Apea, Vanessa, Rubenstein, Emma, Jones, Joyce, Wilkin, Aimee, Ganesan, Anuradha, Henao-Martínez, Andrés F, Chow, Eric J, Titanji, Boghuma K, Zucker, Jason E, Ogoina, Dimie, and Orkin, Chloe M

Published
2022
Full Text
View/download PDF

6. Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society–USA Panel.

Author

Gandhi, Rajesh T., Landovitz, Raphael J., Sax, Paul E., Smith, Davey M., Springer, Sandra A., Günthard, Huldrych F., Thompson, Melanie A., Bedimo, Roger J., Benson, Constance A., Buchbinder, Susan P., Crabtree-Ramirez, Brenda E., del Rio, Carlos, Eaton, Ellen F., Eron Jr, Joseph J., Hoy, Jennifer F., Lehmann, Clara, Molina, Jean-Michel, Jacobsen, Donna M., and Saag, Michael S.

Abstract

Importance: New data and new antiretroviral drugs and formulations continue to become available for the prevention and management of HIV infection. Objective: To provide updated recommendations for HIV treatment and clinical management and HIV prevention. Methods: A panel of volunteer expert physician scientists were appointed to provide updated consensus recommendations for 2024. Relevant evidence in the literature since the last report was identified from PubMed and Embase searches (which initially yielded 3998 unique citations, of which 249 were considered relevant); from ongoing monitoring of the literature by the panel members; from data submitted by product manufacturers; and from studies presented at peer-reviewed scientific conferences between June 2022 and October 2024. Findings: Antiretroviral therapy continues to be recommended for all individuals with HIV. For most people with HIV, initial regimens composed of an integrase strand transfer inhibitor (InSTI), specifically bictegravir or dolutegravir, with 2 (and in some cases 1) nucleoside or nucleotide reverse transcriptase inhibitors are recommended. Recommendations are made for those with particular clinical circumstances, such as pregnancy and active opportunistic diseases, as well as for those unable to take InSTIs. Regimens may need to be changed for virologic failure, adverse effects, convenience, or cost, among other reasons. Long-acting injectable therapy is available for those who prefer not to take daily oral medications and for people struggling with adherence to daily therapy. Recommendations are provided for laboratory monitoring, management of substance use disorders and weight changes, as well as use of statins for cardiovascular disease prevention. For HIV prevention, oral (daily or intermittent) and injectable long-acting medications are effective options for people at increased likelihood of HIV exposure. Further, new tools for maintaining health and well-being among people with HIV, such as doxycycline postexposure prophylaxis to avert sexually transmitted infection, and strategies to treat substance use disorders, are recommended. Disparities in HIV acquisition and care access are discussed and solutions proposed. Conclusions: New approaches for treating and preventing HIV offer additional tools to help end the HIV epidemic, but achieving this goal depends on addressing disparities and inequities in access to care. This Special Communication from the International Antiviral Society–USA provides updated 2024 recommendations for HIV treatment and clinical management and HIV prevention. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

7. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society–USA Panel

Author

Saag, Michael S, Benson, Constance A, Gandhi, Rajesh T, Hoy, Jennifer F, Landovitz, Raphael J, Mugavero, Michael J, Sax, Paul E, Smith, Davey M, Thompson, Melanie A, Buchbinder, Susan P, del Rio, Carlos, Eron, Joseph J, Fätkenheuer, Gerd, Günthard, Huldrych F, Molina, Jean-Michel, Jacobsen, Donna M, and Volberding, Paul A

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Public Health, Immunology, Health Sciences, Medical Microbiology, Sexually Transmitted Infections, HIV/AIDS, Infectious Diseases, Clinical Trials and Supportive Activities, Prevention, Clinical Research, 6.1 Pharmaceuticals, Infection, Good Health and Well Being, Adult, Advisory Committees, Anti-Retroviral Agents, Diagnosis, Differential, Fees, Pharmaceutical, HIV Infections, Humans, Time-to-Treatment, Medical and Health Sciences, General & Internal Medicine, Biomedical and clinical sciences, Health sciences
Abstract

ImportanceAntiretroviral therapy (ART) is the cornerstone of prevention and management of HIV infection.ObjectiveTo evaluate new data and treatments and incorporate this information into updated recommendations for initiating therapy, monitoring individuals starting therapy, changing regimens, and preventing HIV infection for individuals at risk.Evidence reviewNew evidence collected since the International Antiviral Society-USA 2016 recommendations via monthly PubMed and EMBASE literature searches up to April 2018; data presented at peer-reviewed scientific conferences. A volunteer panel of experts in HIV research and patient care considered these data and updated previous recommendations.FindingsART is recommended for virtually all HIV-infected individuals, as soon as possible after HIV diagnosis. Immediate initiation (eg, rapid start), if clinically appropriate, requires adequate staffing, specialized services, and careful selection of medical therapy. An integrase strand transfer inhibitor (InSTI) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) is generally recommended for initial therapy, with unique patient circumstances (eg, concomitant diseases and conditions, potential for pregnancy, cost) guiding the treatment choice. CD4 cell count, HIV RNA level, genotype, and other laboratory tests for general health and co-infections are recommended at specified points before and during ART. If a regimen switch is indicated, treatment history, tolerability, adherence, and drug resistance history should first be assessed; 2 or 3 active drugs are recommended for a new regimen. HIV testing is recommended at least once for anyone who has ever been sexually active and more often for individuals at ongoing risk for infection. Preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine and appropriate monitoring is recommended for individuals at risk for HIV.Conclusions and relevanceAdvances in HIV prevention and treatment with antiretroviral drugs continue to improve clinical management and outcomes for individuals at risk for and living with HIV.

Published
2018

8. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Antinori, Andrea, Apea, Vanessa, Asmuth, David, Avery, Ann, Benson, Paul, Bergin, Colm, Berhe, Mezgebe, Brar, Indira, Brinson, Cynthia, Brunetta, Jason, Burack, Jeffrey, Campbell, Thomas, Cespedes, Michelle, Clarke, Amanda, Coleman, Megan, Coll, Josep, Crespo Casal, Manuel, Creticos, Catherine, Crofoot, Gordon, Cruickshank, Frederick, Cua, Eric, Daar, Eric, de Wet, Joseph, DeJesus, Edwin, Del Romero Guerrero, Jorge, Dinges, William, Doblecki-Lewis, Susanne, Donovan, Taylor, Dosekun, Olamide, Flamm, Jason, Gallant, Joel, Gerstoft, Jan, Gilson, Richard, Gladstein, Jay, Grant, Robert, Grossberg, Robert, Haas, Bernhard, Halperin, Jason, Hardy, W. David, Hare, Charles, Hassler, Shawn, Hengel, Richard, Henry, William, Hodge, Theo, Jr., Hosek, Sybil, Hurt, Christopher, Iandiorio, Michelle, Jessen, Heiko, Kegg, Stephen, Knecht, Gabriele, Kronborg, Gitte, Krznaric, Ivanka, LaMarca, Anthony, Larsen, Carsten Schade, Larsen, Olav Ditlevsen, Lazzarin, Adriano, Leen, Clifford, Lucasti, Christopher, Mallon, Patrick, Mannheimer, Sharon, Markowitz, Martin, Martorell, Claudia, Mayer, Kenneth, Mills, Anthony, Molina, Jean-Michel, Morris, Sheldon, Mounzer, Karam, Nwokolo, Nneka, Ogbuagu, Onyema, Osiyemi, Olayemi, Petroll, Andrew, Philibert, Patrick, Phoenix, John, Pialoux, Gilles, Podzamczer, Daniel, Post, Frank, Prins, Maria, Ramgopal, Moti, Rashbaum, Bruce, Reeves, Iain, Richmond, Gary, Rieger, Armin, Ruane, Peter, Salazar, Laura, Scarsella, Anthony, Schembri, Gabriel, Scott, Mia, Shalit, Peter, Sinclair, Gary, Sobieszczyk, Magdalena, Spinner, Christoph, Stephens, Jeffrey, Szabo, Jason, Taylor, Stephen, Thompson, Melanie, Tremblay, Cecile, Trottier, Benoit, Voskuhl, Gene, Wade, Barbara, Wohl, David, Workowski, Kimberly, Yawetz, Sigal, Young, Benjamin, Ruane, Peter J, Salazar, Laura C, Henry, Keith, Asmuth, David M, Shao, Yongwu, Ebrahimi, Ramin, Cox, Stephanie, Kintu, Alexander, Carter, Christoph, Das, Moupali, Baeten, Jared M, Brainard, Diana M, Whitlock, Gary, Brunetta, Jason M, and Spinner, Christoph D

Published
2021
Full Text
View/download PDF

9. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study

Author

Lataillade, Max, Lalezari, Jacob P, Kozal, Michael, Aberg, Judith A, Pialoux, Gilles, Cahn, Pedro, Thompson, Melanie, Molina, Jean-Michel, Moreno, Santiago, Grinsztejn, Beatriz, Diaz, Ricardo S, Castagna, Antonella, Kumar, Princy N, Latiff, Gulam H, De Jesus, Edwin, Wang, Marcia, Chabria, Shiven, Gartland, Margaret, Pierce, Amy, Ackerman, Peter, and Llamoso, Cyril

Published
2020
Full Text
View/download PDF

10. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

Author

Mayer, Kenneth H, Molina, Jean-Michel, Thompson, Melanie A, Anderson, Peter L, Mounzer, Karam C, De Wet, Joss J, DeJesus, Edwin, Jessen, Heiko, Grant, Robert M, Ruane, Peter J, Wong, Pamela, Ebrahimi, Ramin, Zhong, Lijie, Mathias, Anita, Callebaut, Christian, Collins, Sean E, Das, Moupali, McCallister, Scott, Brainard, Diana M, Brinson, Cynthia, Clarke, Amanda, Coll, Pep, Post, Frank A, and Hare, C Bradley

Published
2020
Full Text
View/download PDF

11. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials

Author

Orkin, Chloe, DeJesus, Edwin, Sax, Paul E, Arribas, Jose R, Gupta, Samir K, Martorell, Claudia, Stephens, Jeffrey L, Stellbrink, Hans-Jurgen, Wohl, David, Maggiolo, Franco, Thompson, Melanie A, Podzamczer, Daniel, Hagins, Debbie, Flamm, Jason A, Brinson, Cynthia, Clarke, Amanda, Huang, Hailin, Acosta, Rima, Brainard, Diana M, Collins, Sean E, and Martin, Hal

Published
2020
Full Text
View/download PDF

12. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society–USA Panel

Author

Günthard, Huldrych F, Saag, Michael S, Benson, Constance A, del Rio, Carlos, Eron, Joseph J, Gallant, Joel E, Hoy, Jennifer F, Mugavero, Michael J, Sax, Paul E, Thompson, Melanie A, Gandhi, Rajesh T, Landovitz, Raphael J, Smith, Davey M, Jacobsen, Donna M, and Volberding, Paul A

Subjects
Biomedical and Clinical Sciences, Public Health, Clinical Sciences, Immunology, Health Sciences, Medical Microbiology, HIV/AIDS, Patient Safety, Infectious Diseases, Sexually Transmitted Infections, Prevention, Clinical Research, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, Infection, Good Health and Well Being, AIDS-Related Opportunistic Infections, Adolescent, Adult, Aged, Anti-Retroviral Agents, CD4 Lymphocyte Count, Drug Therapy, Combination, Female, HIV Infections, HIV-1, Humans, Male, Middle Aged, Post-Exposure Prophylaxis, Pre-Exposure Prophylaxis, Pregnancy, Prognosis, Treatment Failure, Viral Load, Viremia, Young Adult, Medical and Health Sciences, General & Internal Medicine, Biomedical and clinical sciences, Health sciences
Abstract

ImportanceNew data and therapeutic options warrant updated recommendations for the use of antiretroviral drugs (ARVs) to treat or to prevent HIV infection in adults.ObjectiveTo provide updated recommendations for the use of antiretroviral therapy in adults (aged ≥18 years) with established HIV infection, including when to start treatment, initial regimens, and changing regimens, along with recommendations for using ARVs for preventing HIV among those at risk, including preexposure and postexposure prophylaxis.Evidence reviewA panel of experts in HIV research and patient care convened by the International Antiviral Society-USA reviewed data published in peer-reviewed journals, presented by regulatory agencies, or presented as conference abstracts at peer-reviewed scientific conferences since the 2014 report, for new data or evidence that would change previous recommendations or their ratings. Comprehensive literature searches were conducted in the PubMed and EMBASE databases through April 2016. Recommendations were by consensus, and each recommendation was rated by strength and quality of the evidence.FindingsNewer data support the widely accepted recommendation that antiretroviral therapy should be started in all individuals with HIV infection with detectable viremia regardless of CD4 cell count. Recommended optimal initial regimens for most patients are 2 nucleoside reverse transcriptase inhibitors (NRTIs) plus an integrase strand transfer inhibitor (InSTI). Other effective regimens include nonnucleoside reverse transcriptase inhibitors or boosted protease inhibitors with 2 NRTIs. Recommendations for special populations and in the settings of opportunistic infections and concomitant conditions are provided. Reasons for switching therapy include convenience, tolerability, simplification, anticipation of potential new drug interactions, pregnancy or plans for pregnancy, elimination of food restrictions, virologic failure, or drug toxicities. Laboratory assessments are recommended before treatment, and monitoring during treatment is recommended to assess response, adverse effects, and adherence. Approaches are recommended to improve linkage to and retention in care are provided. Daily tenofovir disoproxil fumarate/emtricitabine is recommended for use as preexposure prophylaxis to prevent HIV infection in persons at high risk. When indicated, postexposure prophylaxis should be started as soon as possible after exposure.Conclusions and relevanceAntiretroviral agents remain the cornerstone of HIV treatment and prevention. All HIV-infected individuals with detectable plasma virus should receive treatment with recommended initial regimens consisting of an InSTI plus 2 NRTIs. Preexposure prophylaxis should be considered as part of an HIV prevention strategy for at-risk individuals. When used effectively, currently available ARVs can sustain HIV suppression and can prevent new HIV infection. With these treatment regimens, survival rates among HIV-infected adults who are retained in care can approach those of uninfected adults.

Published
2016

13. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial

Author

Hagins, Debbie P., Osiyemi, Olayemi O., Prelutsky, David James, Ramgopal, Moti N., Scarsella, Anthony John, Dretler, Robin, DeJesus, Edwin, Bettacchi, Christopher J., Sims, James, III, Clay, Patrick G., Bellos, Nicholaos C., Thompson, Melanie A., Montero, Jose, McDonald, Cheryl K., Creticos, Catherine, Shamblaw, David, Mogyoros, Miguel, Terrelonge, Antonio E., Valdes, Martin, Tashima, Karen T., Robbins, William J., Felizarta, Franco Antonio, Elion, Richard A., Slim, Jihad, Win, Sandra S., Lalla-Reddy, Sujata N., Ruane, Peter Jerome, Mills, Anthony, Cade, Jerry L., Dietz, Craig A., Rubin, David Scott, Mayer, Cynthia, Rondon, Juan Carlos, Cook, Paul P., Daar, Eric, Kumar, Princy N., Swindells, Susan, Castro, Jose Guillermo, Melendez-Rivera, Ivan, Morales-Ramirez, Javier O., Santiago, Lizette, Santana-Bagur, Jorge L., Martins, Marcelo, Cahn, Pedro Enrique, Lopardo, Gustavo D., Porteiro, Norma, Bloch, Mark Theo, Baker, David Alfred, Roth, Norman, Moore, Richard James, Finlayson, Robert James, McMahon, James, Rieger, Armin, Zoufaly, Alexander, Hartl, Sylvia, Zangerle, Robert, Smaill, Fiona, Walmsley, Sharon L., Conway, Brian, Rachlis, Anita, Smith, Graham H.R., Perez, Carlos, Afani, Alejandro, Campos, Maria Isabel, Chahin, Carolina Eugenia, Wolff Reyes, Marcelo, Gerstoft, Jan, Weis, Nina, Laursen, Alex Lund, Molina, Jean-Michel, Yazdanpanah, Yazdan, Cotte, Laurent, Raffi, Francois, Morlat, Philippe, Girard, Pierre-Marie, Katlama, Christine, Rockstroh, Juergen K., Arasteh, Keikawus, Esser, Stefan, Stoehr, Albrecht, Stellbrink, Hans-Juergen, Stoll, Matthias, Schuermann, Dirk, Faetkenheuer, Gerd, Bogner, Johannes, Lutz, Thomas, Baumgarten, Axel, Jaeger, Hans, Gori, Andrea, Coltan, Gabriel, Constandis, Felicia, Erscoiu, Simona Manuela, Prisacariu, Liviu-Jany, Rugina, Sorin, Streinu-Cercel, Adrian, Pokrovsky, Vadim Valentinovich, Zakharova, Natalia V., Shuldyakov, Andrey Anatolyevich, Ryamova, Elena Pavlovna, Kulagin, Valeriy Viktorovich, Tsybakova, Olga Aleksandrovna, Orlova-Morozova, Elena, Nagimova, Firaya, Voronin, Evgeniy, Shimonova, Tatyana Evgenyevna, Kozyrev, Oleg Anatolyevich, Orrell, Catherine, Lombaard, Johannes Jurgens, de Jager, Marleen, Portilla Segorb, Joaquin, Mallolas, Josep, Perez Elias, Maria Jesus, Gatell, Josep M., Arribas Lopez, Jose Ramon, Negredo Puigmal, Eugenia, Podzamczer Palter, Daniel, Pulido Ortega, Federico, Troya Garcia, Jesus, De los Santos Gil, Ignacio, Berenguer Berenguer, Juan, Williams, Ian G., Johnson, Margaret A., Schembri, Gabriel, Clarke, Amanda, Gompels, Mark, Fox, Julie Meriel, Taylor, Steven John, Dockrell, David Harold, Kegg, Stephen, Squires, Kathleen, Sax, Paul E, Cahn, Pedro, Lombaard, Johan, Lai, Ming-Tain, Rodgers, Anthony, Lupinacci, Lisa, Kumar, Sushma, Sklar, Peter, Hanna, George J, Hwang, Carey, and Martin, Elizabeth Anne

Published
2020
Full Text
View/download PDF

15. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

Author

Wohl, David A, Yazdanpanah, Yazdan, Baumgarten, Axel, Clarke, Amanda, Thompson, Melanie A, Brinson, Cynthia, Hagins, Debbie, Ramgopal, Moti N, Antinori, Andrea, Wei, Xuelian, Acosta, Rima, Collins, Sean E, Brainard, Diana, and Martin, Hal

Published
2019
Full Text
View/download PDF

17. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

Author

Martins, Marcelo, Cahn, Pedro Enrique, Lopardo, Gustavo D., Porteiro, Norma, Bloch, Mark Theo, Baker, David Alfred, Roth, Norman, Moore, Richard James, Finlayson, Robert James, McMahon, James, Rieger, Armin, Zoufaly, Alexander, Hartl, Sylvia, Zangerle, Robert, Smaill, Fiona, Walmsley, Sharon L., Conway, Brian, Rachlis, Anita, Smith, Graham H.R., Perez, Carlos, Afani, Alejandro, Campos Barker, Maria Isabel E., Chahin, Carolina Eugenia, Wolff Reyes, Marcelo, Gerstoft, Jan, Weis, Nina, Laursen, Alex Lund, Molina, Jean-Michel, Yazdanpanah, Yazdan, Cotte, Laurent, Raffi, Francois, Morlat, Philippe, Girard, Pierre-Marie, Katlama, Christine, Rockstroh, Juergen K., Arasteh, Keikawus, Esser, Stefan, Stoehr, Albrecht, Stellbrink, Hans-Juergen, Stoll, Matthias, Schuermann, Dirk, Faetkenheuer, Gerd, Bogner, Johannes, Lutz, Thomas, Baumgarten, Axel, Jaeger, Hans, Gori, Andrea, Coltan, Gabriel, Constandis, Felicia, Erscoiu, Simona Manuela, Prisacariu, Liviu-Jany, Rugina, Sorin, Streinu-Cercel, Adrian, Pokrovsky, Vadim Valentinovich, Zakharova, Natalia V., Shuldyakov, Andrey Anatolyevich, Ryamova, Elena Pavlovna, Kulagin, Valeriy Viktorovich, Tsybakova, Olga Aleksandrovna, Orlova-Morozova, Elena, Nagimova, Firaya, Voronin, Evgeniy, Shimonova, Tatyana Evgenyevna, Kozyrev, Oleg Anatolyevich, Orrell, Catherine, Lombaard, Johannes Jurgens, Botes, Margaretha Elizabeth, Portilla, Joaquin, Gatell, Josep Maria, Perez, Maria Jesus, Arribas, Jose Ramon, Negredo, Eugenia, Podzamczer, Daniel, Pulido, Federico, Troya, Jesus, De los Santos, Ignacio, Berenguer, Juan, Williams, Ian G., Johnson, Margaret A., Schembri, Gabriel, Clarke, Amanda, Gompels, Mark, Fox, Julie Meriel, Taylor, Steven John, Kegg, Stephen, Hagins, Debbie P., Osiyemi, Olayemi O., Prelutsky, David James, Ramgopal, Moti N., Dretler, Robin, DeJesus, Edwin, Sloan, Louis, Lewis, Stanley T., Clay, Patrick G., Bellos, Nicholaos C., Thompson, Melanie A., Montero, Jose, McDonald, Cheryl K., Creticos, Catherine, Shamblaw, David, Terrelonge, Antonio E., Valdes, Martin, Tashima, Karen T., Robbins, William J., Felizarta, Franco Antonio, Elion, Richard A., Slim, Jihad, Lalezari, Jacob Paul, Lalla-Reddy, Sujata N., Ruane, Peter Jerome, Mills, Anthony, Cade, Jerry L., Campo, Rafael E., Dietz, Craig A., Blick, Gary, Mayer, Cynthia, Rondon, Juan Carlos, Cook, Paul P., Daar, Eric, Kumar, Princy N., Swindells, Susan, Castro, Jose Guillermo, Morales-Ramirez, Javier O., Santiago, Lizette, Santana-Bagur, Jorge L., Squires, Kathleen, Sax, Paul E, Cahn, Pedro, Lombaard, Johan, Lai, Ming-Tain, Xu, Xia, Rodgers, Anthony, Lupinacci, Lisa, Kumar, Sushma, Sklar, Peter, Nguyen, Bach-Yen, Hanna, George J, and Hwang, Carey

Published
2018
Full Text
View/download PDF

23. Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib

Author

Kumar, Shaji K., LaPlant, Betsy R., Reeder, Craig B., Roy, Vivek, Halvorson, Alese E., Buadi, Francis, Gertz, Morie A., Bergsagel, P. Leif, Dispenzieri, Angela, Thompson, Melanie A., Crawley, Jamie, Kapoor, Prashant, Mikhael, Joseph, Stewart, Keith, Hayman, Suzanne R., Hwa, Yi L., Gonsalves, Wilson, Witzig, Thomas E., Ailawadhi, Sikander, Dingli, David, Go, Ronald S., Lin, Yi, Rivera, Candido E., Rajkumar, S. Vincent, and Lacy, Martha Q.

Published
2016
Full Text
View/download PDF

25. Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial

Author

Lalezari, Jacob P, Latiff, Gulam H, Brinson, Cynthia, Echevarría, Juan, Treviño-Pérez, Sandra, Bogner, Johannes R, Thompson, Melanie, Fourie, Jan, Sussmann Pena, Otto A, Mendo Urbina, Fernando C, Martins, Marcelo, Diaconescu, Iulian G, Stock, David A, Joshi, Samit R, Hanna, George J, and Lataillade, Max

Published
2015
Full Text
View/download PDF

26. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

Author

Sax, Paul E, Wohl, David, Yin, Michael T, Post, Frank, DeJesus, Edwin, Saag, Michael, Pozniak, Anton, Thompson, Melanie, Podzamczer, Daniel, Molina, Jean Michel, Oka, Shinichi, Koenig, Ellen, Trottier, Benoit, Andrade-Villanueva, Jaime, Crofoot, Gordon, Custodio, Joseph M, Plummer, Andrew, Zhong, Lijie, Cao, Huyen, Martin, Hal, Callebaut, Christian, Cheng, Andrew K, Fordyce, Marshall W, and McCallister, Scott

Published
2015
Full Text
View/download PDF

27. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

Author

Gandhi, Rajesh T., primary, Bedimo, Roger, additional, Hoy, Jennifer F., additional, Landovitz, Raphael J., additional, Smith, Davey M., additional, Eaton, Ellen F., additional, Lehmann, Clara, additional, Springer, Sandra A., additional, Sax, Paul E., additional, Thompson, Melanie A., additional, Benson, Constance A., additional, Buchbinder, Susan P., additional, del Rio, Carlos, additional, Eron, Joseph J., additional, Günthard, Huldrych F., additional, Molina, Jean-Michel, additional, Jacobsen, Donna M., additional, and Saag, Michael S., additional

Published
2023
Full Text
View/download PDF

30. Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials

Author

Orkin, Chloe, Molina, Jean-Michel, Cahn, Pedro, Lombaard, Johannes, Supparatpinyo, Khuanchai, Kumar, Sushma, Campbell, Havilland, Wan, Hong, Teal, Valerie, Jin Xu, Zhi, Asante-Appiah, Ernest, Sklar, Peter, Teppler, Hedy, Lahoulou, Rima, Martins, Marcelo D, Cahn, Pedro E, Lopardo, Gustavo D, Porteiro, Norma, Bloch, Mark Theo, Baker, David Alfred, Roth, Norman, Moore, Richard J, Finlayson, Robert James, McMahon, James, Rieger, Armin, Zoufaly, Alexander, Schmied, Brigitte, Hartl, Sylvia, Zangerle, Robert, Smaill, Fiona, Walmsley, Sharon L, Conway, Brian, Rachlis, Anita, Smith, Graham H R, Perez Cortes, Carlos, Afani, Alejandro, Campos Barker, Maria Isabel E, Chahin Anania, Carolina Eugenia, Reyes, Marcelo J. Wolff, Gerstoft, Jan, Weis, Nina, Laursen, Alex Lund, Molina, Jean-Michel, Yazdanpanah, Yazdan, Cotte, Laurent, Raffi, Francois, Slama, Laurence, Morlat, Philippe, Girard, Pierre-Marie, Katlama, Christine, Rockstroh, Juergen K, Arasteh, Keikawus, Esser, Stefan, Stoehr, Albrecht, Stellbrink, Hans-Juergen, Stoll, Matthias, Schuermann, Dirk, Faetkenheuer, Gerd, Bogner, Johannes Richard, Lutz, Thomas, Baumgarten, Axel, Jaeger, Hans, Wiese, Carmen, Gori, Andrea, Migliorino, Guglielmo Marco, Coltan, Gabriel, Constandis, Felicia, Erscoiu, Simona M, Prisacariu, Liviu-Jany, Rugina, Sorin, Streinu-Cercel, Adrian, Pokrovsky, Vadim V, Zakharova, Natalia, Shuldyakov, Andrey Anatolyevich, Ryamova, Elena Pavlovna, Kulagin, Valeriy Viktorovich, Tsybakova, Olga Aleksandrovna, Orlova-Morozova, Elena, Nagimova, Firaya, Voronin, Evgeniy, Shimonova, Tatiana Evgenyevna, Kozyrev, Oleg Anatolyevich, Orrell, Catherine, Lombaard, Johannes Jurgens, Botes, Margaretha Elizabeth, de Jager, Marleen, Segorb, Joaquin Portilla, Gatell Artigas, Josep Maria, Mallolas Masferrer, Josep, Guillen, Santiago Moreno, Perez Elias, Maria Jesus, Arribas Lopez, Jose R, Puigmal, Eugenia Negredo, Podzamczer Palter, Daniel, Ortega, Frederico Pulido, Garcia, Jesus Troya, de los Santos Gil, Ignacio, Berenguer, Juan, Nelson, Mark Richard, Williams, Ian G, Johnson, Margaret A, Khoo, Saye, Schembri, Gabriel, Clarke, Amanda, Gompels, Mark, Fox, Julie Meriel, Lwanga, Julianne, Taylor, Steven John, Dockrell, David Harold, Kegg, Stephen, Hagins, Debbie P, Osiyemi, Olayemi O, Prelutsky, David James, Ramgopal, Moti N, Scarsella, Anthony J, Dretler, Robin, DeJesus, Edwin, Bettacchi, Christopher J, Sims III, James, Clay, Patrick G, Bellos, Nicholaos C, Thompson, Melanie A, Montero, Jose, McDonald, Cheryl K, Creticos, Catherine, Shamblaw, David, Terrelonge, Antonio E, Valdes, Martin, Tashima, Karen T, Robbins, William J, Elion, Richard A, Goldstein, Deborah, Slim, Jihad, Lalezari, Jacob Paul, Pushkin, Richard, Lalla-Reddy, Sujata N, Win, Sanda S, Ruane, Peter Jerome, Mills, Anthony Martin, Cade, Jerry L, Campo, Rafael, Dietz, Craig A, Hoffman-Terry, Margaret, Blick, Gary, Rubin, David Scott, Mayer, Cynthia, Rondon, Juan Carlos, Cook, Paul P, Daar, Eric, Kumar, Princy N, Swindells, Susan, Castro, Jose Guillermo, Morales-Ramirez, Javier O, Santiago, Lizette, Santana-Bagur, Jorge L, Vandekerckhove, Linos, Florence, Eric, De Wit, Stephane, Derdelinckx, Inge, Vandercam, Bernard, Belkhir, Leila, De Wet, Joseph, Lebouche, Bertrand, Trottier, Benoit, Longpre, Daniele, Szabo, Jason, LeBlanc, Roger P, Jensen, Werner, Gonzalez, Alvaro Rojas, Beltran, Carlos, Sussmann, Otto Alberto, Velez, Juan Diego, Onate, Jose Millan, Nielsen, Henrik, Degen, Olaf, Stephan, Christoph, Arathoon, Eduardo, Lopez, Rudy Manuel, Rojas Alvarado, Evelyn Michelle, Gonzalez Patzan, Luis Demetrio, Meija, Carlos R, Pinzon, Rodolfo, Parchment, Charles, Sthoeger, Zev, Chowers, Michal, Riesenberg, Klaris, Shahar, Eduardo, Levy, Itzchak, Quintero Perez, Nora Patricia, Andrade-Villanueva, Jaime Federico, Crabtree Ramirez, Brenda Eloisa, Rijnders, Bart, den Hollander, Jan G, Handy, Rupert, Morales, Nilo Bonifacio, Hidalgo, Jose Alfredo, Infante, Rosa Mercedes, Matos Prado, Eduardo Demetrio, Campos, Pablo E, Ticona Chaves, Eduardo Romulo, Pinedo, Yvett, Pacheco, Patricia, Maltez, Fernando Manuel, Cunha, Jose, Neves, Isabel, Serrao, Rosario, Melendez-Rivera, Ivan, Mendoza-Rodriguez, Rafael O, Maldonado-Rivera, Sandra, Ortiz-Lasanta, Grisell, Kizhlo, Svetlana, Freud, Hernando Knobel, Moreno, Jose Sanz, Mendez, Francisco Vera, Mohapi, Lerato, Mitha, Essack Aziz, Mahomed, Akbar Anvar, Fouche, Leon Frederik, Kaplan, Richard, Siddique, Naeem, Hoosen, Farzana, Rassool, Mohammed Siddique, Baraldi, Ezio, Calmy, Alexandra, Cavassini, Matthias, Fehr, Jan, Tsai, Hung-Chin, Lin, Hsi-Hsun, Huang, Chun-Kai, Ko, Wen-Chien, Lin, Yu-Hui, Chen, Su-Jung, Hung, Chien-Ching, Avihingsanon, Anchalee, Kiertiburanakul, Sasisopin, Ratanasuwan, Winai, Supparatpinyo, Khuanchai, Chetchotisakd, Ploenchan, Changpradub, Dhitiwat, Orkin, Chloe, Fox, Ashini, Winston, Alan, Ustianowski, Andrew, Yangco, Bienvenido G, Asmuth, David Michael, Vigil, Karen J, Berger, Daniel S, Bhatti, Laveeza, Campbell, Thomas, Casey, Kathleen K, Liu, Edward, Crofoot, Gordon E, Cunningham, Douglas, Feinberg, Judith, Fichtenbaum, Carl, Balamban Felizarta, Franco Antonio, Jefferson, Thomas T, Johnson, Marc Alexander, Lewis, Stanley T, Luque, Amneris E, Novak, Richard M, Sloan, Louis, Sweet, Donna E, Towner, William J, Zane, Ryan, Riedel, David J, Loftus, Richard Anton, Shon, Alyssa So Young, Mogyoros, Miguel, Tebas, Pablo, Scott, Mia Louise, Parenti, David M, and Inciarte Portillo, Alexy

Abstract

In two phase 3 trials for first-line therapy in adults with HIV-1, doravirine showed non-inferior efficacy, a favourable safety profile, and a superior lipid profile to darunavir and efavirenz through to 48 and 96 weeks. Here we report 192-week results from both studies.

Published
2024
Full Text
View/download PDF

31. Fixed Duration Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone Quadruplet for Newly Diagnosed Multiple Myeloma - MRD Negativity and Survival Outcomes

Author

Kumar, Shaji K, primary, Laplant, Betsy, additional, Asmus, Erik J, additional, Buadi, Francis K., additional, Gonsalves, Wilson I., additional, Muchtar, Eli, additional, Dingli, David, additional, Thompson, Melanie Ann, additional, Go, Ronald, additional, Warsame, Rahma M, additional, Kourelis, Taxiarchis, additional, Hwa, Yi L., additional, Fonder, Amie, additional, Hobbs, Miriam A., additional, Lacy, Martha Q., additional, Dispenzieri, Angela, additional, Hayman, Suzanne R., additional, Leung, Nelson, additional, Binder, Moritz, additional, Rajkumar, S. Vincent, additional, Gertz, Morie A, additional, and Kapoor, Prashant, additional

Published
2022
Full Text
View/download PDF

36. Antiviral Activity of Single-Dose PRO 140, a CCR5 Monoclonal Antibody, in HIV-Infected Adults

Author

Jacobson, Jeffrey M., Saag, Michael S., Thompson, Melanie A., Fischl, Margaret A., Liporace, Ralph, Reichman, Richard C., Redfield, Robert R., Fichtenbaum, Carl J., Zingman, Barry S., Patel, Mahesh C., Murga, Jose D., Pemrick, Suzanne M., D'Ambrosio, Paul, Michael, Marti, Kroger, Hans, Ly, Hieu, Rotshteyn, Yakov, Buice, Robert, Morris, Stephen A., Stavola, Joseph J., Maddon, Paul J., Kremer, Alton B., and Olson, William C.

Published
2008
Full Text
View/download PDF

38. Human Monkeypox Virus Infection in Women During the 2022 Outbreaks – a Global Case Series

Author

Thornhill, John Patrick, primary, Palich, Romain, additional, Ghosn, Jade, additional, Walmsley, Sharon, additional, Moschese, Davide, additional, Cortes, Claudia P., additional, Galliez, Rafael M., additional, Garlin, Amy B., additional, Nozza, Silvia, additional, Mitja, Oriol, additional, Radix, Asa E., additional, Blanco, Jose, additional, Crabtree-Ramirez, Brenda, additional, Thompson, Melanie, additional, Wiese, Lothar, additional, Schulbin, Hubert, additional, Levocvich, Ariela, additional, Falcone, Marco, additional, Lucchini, Anna, additional, Sendagorta, Elena, additional, Treutiger, Carl Johan, additional, Byrne, Ruth, additional, Coyne, Katherine, additional, Meyerowitz, Eric A., additional, Grahn, Anna M., additional, Eg.Hansen, Ann-Brit, additional, Pourcher, Valérie, additional, Piazza, Michelle Dalla, additional, Lee, Rachel, additional, Stoeckle, Marcel, additional, Hazra, Aniruddha, additional, Apea, Vanessa, additional, Rubenstein, Emma, additional, Jones, Joyce, additional, Wilkin, Aimee, additional, Ganesan, Anuradha, additional, Henao-Martínez, Andrés, additional, Chow, Eric J., additional, Titanji, Boghuma K., additional, Zucker, Jason, additional, Ogoina, Dimie, additional, Orkin, Chloe, additional, and Group, SHARE NET Writing, additional

Published
2022
Full Text
View/download PDF

40. Safety and Antiviral Activity at 48 Weeks of Lopinavir/Ritonavir Plus Nevirapine and 2 Nucleoside Reverse-Transcriptase Inhibitors in Human Immunodeficiency Virus Type 1-Infected Protease Inhibitor-Experienced Patients

Author

Benson, Constance A., Deeks, Steven G., Brun, Scott C., Gulick, Roy M., Eron, Joseph J., Kessler, Harold A., Murphy, Robert L., Hicks, Charles, King, Martin, Wheeler, David, Feinberg, Judith, Stryker, Richard, Sax, Paul E., Riddler, Sharon, Thompson, Melanie, Real, Kathryn, Hsu, Ann, Kempf, Dale, Japour, Anthony J., and Sun, Eugene

Published
2002

42. Efficacy Testing of Recombinant Human Immunodeficiency Virus (HIV) gp160 as a Therapeutic Vaccine in Early-Stage HIV-1-Infected Volunteers

Author

rgp160 Phase II Vaccine Investigators, Birx, Deborah L., Loomis-Price, Lawrence D., Aronson, Naomi, Brundage, John, Davis, Charles, Deyton, Lawrence, Garner, Robin, Gordin, Fred, Henry, David, Holloway, William, Kerkering, Thomas, Luskin-Hawk, Roberta, McNeil, John, Michael, Nelson, Pierce, Phillip Foster, Poretz, Donald, Ratto-Kim, Silvia, Renzullo, Phil, Ruiz, Nancy, Sitz, Karl, Smith, Gale, Tacket, Carol, Thompson, Melanie, Tramont, Edmond, Yangco, Bienvenido, Yarrish, Robert, and Redfield, Robert R.

Published
2000

45. Antiretroviral treatment of adult HIV infection

Author

Thompson, Melanie A., Aberg, Judith A., Cahn, Pedro, Montaner, Julio S.G., Rizzardini, Giuliano, Volberding, Paul A., Yeni, Patrick, Schooley, Robert T., Jacobsen, Donna M., Reiss, Peter, Richman, Douglas D., Gunthard, Huldrych F., Hammer, Scott M., Hirsch, Martin S., Telenti, Amalio, and Gatell, Jose M.

Subjects
HIV infection -- Drug therapy, Antiviral agents -- Diagnosis, Antiviral agents -- Risk factors, Antiviral agents -- Care and treatment
Abstract

The study aims to investigate and provide updated recommendations for the management and antiretroviral treatment (ART) of adults with HIV and selection of appropriate regimes and monitoring of such patients. The results indicate that patient readiness is essential and ART should be recommended for asymptomatic patients with a CD cell count less than or equal to 500 as well as symptomatic ones and regular monitoring of such patients should be undertaken with treatment failure managed early.

Published
2010

47. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Ogbuagu, Onyema, primary, Ruane, Peter J, additional, Podzamczer, Daniel, additional, Salazar, Laura C, additional, Henry, Keith, additional, Asmuth, David M, additional, Wohl, David, additional, Gilson, Richard, additional, Shao, Yongwu, additional, Ebrahimi, Ramin, additional, Cox, Stephanie, additional, Kintu, Alexander, additional, Carter, Christoph, additional, Das, Moupali, additional, Baeten, Jared M, additional, Brainard, Diana M, additional, Whitlock, Gary, additional, Brunetta, Jason M, additional, Kronborg, Gitte, additional, Spinner, Christoph D, additional, Antinori, Andrea, additional, Apea, Vanessa, additional, Asmuth, David, additional, Avery, Ann, additional, Benson, Paul, additional, Bergin, Colm, additional, Berhe, Mezgebe, additional, Brar, Indira, additional, Brinson, Cynthia, additional, Brunetta, Jason, additional, Burack, Jeffrey, additional, Campbell, Thomas, additional, Cespedes, Michelle, additional, Clarke, Amanda, additional, Coleman, Megan, additional, Coll, Josep, additional, Crespo Casal, Manuel, additional, Creticos, Catherine, additional, Crofoot, Gordon, additional, Cruickshank, Frederick, additional, Cua, Eric, additional, Daar, Eric, additional, de Wet, Joseph, additional, DeJesus, Edwin, additional, Del Romero Guerrero, Jorge, additional, Dinges, William, additional, Doblecki-Lewis, Susanne, additional, Donovan, Taylor, additional, Dosekun, Olamide, additional, Flamm, Jason, additional, Gallant, Joel, additional, Gerstoft, Jan, additional, Gladstein, Jay, additional, Grant, Robert, additional, Grossberg, Robert, additional, Haas, Bernhard, additional, Halperin, Jason, additional, Hardy, W. David, additional, Hare, Charles, additional, Hassler, Shawn, additional, Hengel, Richard, additional, Henry, William, additional, Hodge, Theo, additional, Hosek, Sybil, additional, Hurt, Christopher, additional, Iandiorio, Michelle, additional, Jessen, Heiko, additional, Kegg, Stephen, additional, Knecht, Gabriele, additional, Krznaric, Ivanka, additional, LaMarca, Anthony, additional, Larsen, Carsten Schade, additional, Larsen, Olav Ditlevsen, additional, Lazzarin, Adriano, additional, Leen, Clifford, additional, Lucasti, Christopher, additional, Mallon, Patrick, additional, Mannheimer, Sharon, additional, Markowitz, Martin, additional, Martorell, Claudia, additional, Mayer, Kenneth, additional, Mills, Anthony, additional, Molina, Jean-Michel, additional, Morris, Sheldon, additional, Mounzer, Karam, additional, Nwokolo, Nneka, additional, Ogbuagu, Onyema, additional, Osiyemi, Olayemi, additional, Petroll, Andrew, additional, Philibert, Patrick, additional, Phoenix, John, additional, Pialoux, Gilles, additional, Post, Frank, additional, Prins, Maria, additional, Ramgopal, Moti, additional, Rashbaum, Bruce, additional, Reeves, Iain, additional, Richmond, Gary, additional, Rieger, Armin, additional, Ruane, Peter, additional, Salazar, Laura, additional, Scarsella, Anthony, additional, Schembri, Gabriel, additional, Scott, Mia, additional, Shalit, Peter, additional, Sinclair, Gary, additional, Sobieszczyk, Magdalena, additional, Spinner, Christoph, additional, Stephens, Jeffrey, additional, Szabo, Jason, additional, Taylor, Stephen, additional, Thompson, Melanie, additional, Tremblay, Cecile, additional, Trottier, Benoit, additional, Voskuhl, Gene, additional, Wade, Barbara, additional, Workowski, Kimberly, additional, Yawetz, Sigal, additional, and Young, Benjamin, additional

Published
2021
Full Text
View/download PDF

48. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel

Author

Hammer, Scott M., Eron, Joseph J. Jr., Reiss, Peter, Schooley, Robert T., Thompson, Melanie A., Walmsley, Sharon, Cahn, Pedro, Fischl, Margaret A., Gatell, Jose M., Hirsch, Martin S., Jacobsen, Donna M., Montaner, Julio S.G., Richman, Douglas D., Yeni, Patrick G., and Volberding, Paul A.

Subjects
HIV infection -- Drug therapy, HIV infection -- Risk factors, Antiviral agents -- Health aspects, Medical care -- Quality management
Abstract

The evaluation of the new data in the field of HIV and recommendations for antiretroviral treatment (ART) and management of HIV is reported. Results indicated that the recommendations of the International AIDS Society need to be implemented to provide quality care to different kinds of population infected with AIDS.

Published
2008

49. Implementation and evaluation of a clinic-based behavioral intervention: positive steps for patients with HIV

Author

Gardner, Lytt I., Marks, Gary, O'Daniels, Christine M., Wilson, Tracey E., Golin, Carol, Wright, Julie, Quinlivan, E. Byrd, Bradley-Springer, Lucy, Thompson, Melanie, Raffanti, Stephen, and Thrun, Mark

Subjects
AIDS treatment -- Methods, AIDS treatment -- Training, HIV infection -- Care and treatment, HIV infection -- Prevention, Medical personnel -- Training, Medical personnel -- Practice, Health
Abstract

We conducted a demonstration project to design, implement, and evaluate a risk-reduction intervention delivered by medical providers to patients with HIV during routine care in 2005 and 2006. Medical providers at seven HIV clinics in the United States received training to deliver an intervention in which they screened patients for behavioral risks, gave targeted counseling, and delivered prevention messages. A longitudinal cohort (n = 767) of patients completed a baseline questionnaire and two follow-up questionnaires (6-month intervals) after the intervention was initiated. Logistic regression and generalized estimating equations (GEE) methods were used in analyses. The cohort had a median age of 41, was 58% black, 28% white, and 10% Hispanic; 32% were women and 42% self-identified as men who have sex with men. The 3-month prevalence of unprotected anal or vaginal intercourse (UAVI) with any partners declined significantly (p < 0.001) from baseline (42%) to follow-up (26% at first follow-up, 23% at second follow-up). The decline was significant with partners who were HIV-negative/unknown serostatus or HIV-positive. Cohort patients' self-reported receipt of safer-sex counseling at all, some, or no clinic visits during the interval between baseline and first follow-up showed a dose-response relationship with decline in prevalence of UAVI in that interval, with relative reductions of 45%, 35%, and 19%, respectively. All findings were confirmed in multivariate models that controlled for demographic factors and HIV clinical status of participants. This project demonstrated that with only brief training, HIV medical providers successfully conducted an HIV prevention intervention with their clinic patients. Our findings indicate that clinics that serve HIV patients can incorporate such programs as standard of care.

Published
2008

50. INSIGHTS: Kemp must act now to contain COVID-19

Author

Couk, Jesse, Lukashok, Sophie, and Thompson, Melanie

Subjects
COVID-19, General interest, News, opinion and commentary
Abstract

Byline: Jesse Couk, Sophie Lukashok, Melanie Thompson As the state of Georgia faces once again an increasing number of COVID-19 cases, we must act swiftly to avoid a potential critical [...]

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results